3i Invests In Leading Xylitol Manufacturer
This article was originally published in PharmAsia News
3i, the world's leading company in private equity and venture capital, announced that it will invest in Chinese firm Futian Pharmaceutical and become a minority shareholder. 3i did not disclose details about the investment. Futian, based in Yu City, Shandong Province, is a major xylitol manufacturer with many international customers. 3i's investment in Futian will inject capital and strengthen the latter's management team to further help establish its global position and bring new expansion opportunities. (Click here for more - Chinese Language)
You may also be interested in...
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.